Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Research article

Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis

AM Fietta14*, AM Bardoni2, R Salvini2, I Passadore1, M Morosini1, L Cavagna34, V Codullo34, E Pozzi14, F Meloni14 and C Montecucco34

Author Affiliations

1 Department of Haematological, Pneumological and Cardiovascular Sciences, University of Pavia, Via Taramelli 5, 27100 Pavia, Italy

2 Department of Biochemistry, University of Pavia, Via Taramelli 5, 27100 Pavia, Italy

3 Department of Internal Medicine, University of Pavia, Via Taramelli 5, 27100 Pavia, Italy

4 IRCCS San Matteo, Piazzale Golgi 2, 27100 Pavia, Italy

For all author emails, please log on.

Arthritis Research & Therapy 2006, 8:R160  doi:10.1186/ar2067

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/8/6/R160


Received:7 March 2006
Revisions received:31 May 2006
Accepted:17 October 2006
Published:17 October 2006

© 2006 Fietta et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Lung fibrosis is a major cause of mortality and morbidity in systemic sclerosis (SSc). However, its pathogenesis still needs to be elucidated. We examined whether the alteration of certain proteins in bronchoalveolar lavage fluid (BALF) might have a protective or a causative role in the lung fibrogenesis process. For this purpose we compared the BALF protein profile obtained from nine SSc patients with lung fibrosis (SScFib+) with that obtained from six SSc patients without pulmonary fibrosis (SScFib-) by two-dimensional gel electrophoresis (2-DE). Only spots and spot-trains that were consistently expressed in a different way in the two study groups were taken into consideration. In total, 47 spots and spot-trains, corresponding to 30 previously identified proteins in human BALF, showed no significant variation between SScFib+ patients and SScFib- patients, whereas 24 spots showed a reproducible significant variation in the two study groups. These latter spots corresponded to 11 proteins or protein fragments, including serum albumin fragments (13 spots), 5 previously recognized proteins (7 spots), and 4 proteins (3 spots) that had not been previously described in human BALF maps, namely calumenin, cytohesin-2, cystatin SN, and mitochondrial DNA topoisomerase 1 (mtDNA TOP1). Mass analysis did not determine one protein-spot. The two study groups revealed a significant difference in BALF protein composition. Whereas levels of glutathione S-transferase P (GSTP), Cu–Zn superoxide dismutase (SOD) and cystatin SN were downregulated in SScFib+ patients compared with SScFib- patients, we observed a significant upregulation of α1-acid glycoprotein, haptoglobin-α chain, calgranulin (Cal) B, cytohesin-2, calumenin, and mtDNA TOP1 in SScFib+ patients. Some of these proteins (GSTP, Cu–Zn SOD, and cystatin SN) seem to be involved in mechanisms that protect lungs against injury or inflammation, whereas others (Cal B, cytohesin-2, and calumenin) seem to be involved in mechanisms that drive lung fibrogenesis. Even if the 2-DE analysis of BALF did not provide an exhaustive identification of all BALF proteins, especially those of low molecular mass, it allows the identification of proteins that might have a role in lung fibrogenesis. Further longitudinal studies on larger cohorts of patients will be necessary to assess their usefulness as predictive markers of disease.

Introduction

The analysis of the bronchoalveolar lavage fluid (BALF) proteome can potentially provide important information about changes in protein expression and secretion during the course of pulmonary disorders. At the moment, more than 100 human proteins or protein isoforms have been identified in human BALF by using two-dimensional gel electrophoresis (2-DE), including both proteins released locally in the lung by inflammatory or epithelial cells and proteins derived from serum by diffusion across the capillary–alveolar barrier [1,2]. Previous studies showed that the protein composition of BALF was altered in sarcoidosis, idiopathic pulmonary fibrosis, allergic asthma, and chronic obstructive pulmonary disease [3-5]. Furthermore, Rottoli and colleagues [6] recently demonstrated that systemic sclerosis patients with pulmonary fibrosis (SScFib+) showed a BALF profile that was intermediate between that of patients with sarcoidosis and idiopatic pulmonary fibrosis, despite some particularities.

Systemic sclerosis (SSc) is an autoimmune disorder of unknown origin, characterized by an excessive deposition of collagen and other extracellular matrix proteins on the skin as well as multiple internal organs, alterations in microvasculature, and humoral and cellular abnormalities [7]. Clinically, the disease is very heterogeneous, ranging from limited skin involvement with limited systemic alterations to clinical pictures with diffuse skin sclerosis and severe visceral involvement with fibrosis, microvascular abnormalities and mononuclear cell infiltration of the gastrointestinal tract, lungs, heart, and kidneys. Pulmonary involvement has emerged as potentially the most serious visceral lesion in SSc. Alveolitis is more commonly seen in SSc with diffuse skin sclerosis, particularly in the presence of serum anti-topoisomerase I (anti-Scl70) antibodies, but only 15% of patients eventually reach severe end-stage lung fibrosis [8].

Given the complexity of the pathogenesis of lung fibrosis and the lack of biological markers that can reliably predict which patients will evolve the disease, great interest has been shown in these issues, also comparing cohorts of SSc patients with or without lung involvement. The ability to identify the proteins that are differently expressed in the lower airways of SScFib+ patients from those in SScFib- patients might provide new insight into the disease pathogenesis and into the identification of possible protein biomarkers of the disease's progression. With this aim, we used the 2-DE analysis to assess and compare the protein profile of BALFs from a group of SScFib+ and SScFib- patients, respectively.

Materials and methods

Patients

The samples consisted of archived BALF samples acquired between March 2004 and April 2005 from 15 SSc patients who satisfied the preliminary American College of Rheumatology criteria for disease classification [9]. All the patients were female and non-smoker outpatients at the Rheumatology Unit of the Policlinico San Matteo, Pavia, Italy. They all gave their informed consent to undergo bronchoscopy, and none were being treated with prednisone or other immunosuppressive agents at the time of enrollment. Five patients had SSc with limited skin involvement and 10 had SSc with diffuse skin sclerosis; indirect immunofluorescence on Hep-2 cells detected the antinuclear antibodies, and the anti-Scl70 antibodies were evaluated by enzyme-linked immunosorbent assay (Diamedix Co., Miami, FL, USA). All the patients tested positive for antinuclear antibodies, and nine had anti-Scl70 antibodies.

The diagnosis of SSc-associated lung fibrosis was based on clinical, functional and radiographic signs. In all the cases, carbon monoxide transfer, forced vital capacity, chest radiography, and high-resolution computed tomography (HRCT) determined the respiratory involvement, which was defined as at least a grade 1 severity on the disease severity scale for SSc [10]. In all the cases, the same expert radiologist calculated the Kazerooni score for fibrosis as described previously [11]. Nine patients showed a decrease of at least 20% with regard to the expected carbon monoxide transfer or forced vital capacity values [12]. This decrease was associated with abnormal chest radiograph and the presence of significant fibrosis on the HRCT scan (mean Kazerooni fibrosis score: 10 ± 5 SD). These nine patients were included in the SScFib+ group. The remaining six patients, who revealed no evidence of lung involvement either on the lung function tests or on the HRCT scan (absence of fibrosis and/or a ground-glass pattern), were included in the SScFib- group. Table 1 details the patients' demographic, clinical, immunological and functional characteristics.

Table 1. Demographic, clinical, immunological and functional characteristics of scleroderma patients

Bronchoalveolar lavage and phenotype analysis

Bronchoalveolar lavage (BAL) was performed as described previously [13]. To summarize briefly, the distal tip of the bronchoscope was wedged into the middle lobe or lingular bronchus. A total of 150 ml of warm sterile saline solution were instilled in 30 ml aliquots and serially recovered by gentle aspiration. The first collected aliquot was used for the microscopic and cultural examination of common bacteria and fungi, and of direct acid-fast bacilli smears (Kinyoun method) and cultures for mycobacteria, and for the microscopic examination of Pneumocystis jiroveci (Gomori-Grocott silver stain). All the other aliquots were used to assess the total and differential cell counts (performed on cyto-centrifuged preparations with the use of May–Grünwald–Giemsa and Papanicolaou stainings) and the percentages of CD4+ and CD8+ T cells (assessed by cytofluorimetry). Samples were immediately filtered twice through gauze, then centrifuged at 1,500 r.p.m. for 10 min, and BALF samples were promptly frozen in aliquots and stored at -80°C until used.

Two-dimensional gel electrophoresis

BALF samples were dialyzed (tubing cut-off 1 kDa) for a few days against several changes of distilled water, in the presence of protease inhibitors (protease inhibitor cocktail; Sigma, St Louis, MO, USA), and the protein content was assessed (bicinchoninic acid protein assay kit; Pierce, Rockford, IL, USA). Samples were freeze-dried and pellets were suspended in 8 M urea, 4% w/v CHAPS, 65 mM 1,4-dithioerythritol (solution A). Two-dimensional gel electrophoresis was performed as described previously [14]. In brief, for each analytical experiment the same amount (70 μg) of proteins was loaded on immobilized pH gradient (IPG) strips (pH 3.5 to 10, 18 cm; Amersham Biosciences, Uppsala, Sweden), which were swollen in solution A plus 0.8% carrier ampholytes (Ampholine™, pH 3.5 to 10 for IEF; Amersham Biosciences) and a trace of bromophenol blue. A larger amount of protein (1 mg) had to be loaded for identification by mass spectrometry (MS). Rehydration was performed in the strip holder of the IPGphor system at 20°C (Amersham Biosciences) and isoelectrofocusing was terminated at 60 kV h. The IPG strips were equilibrated first for 12 minutes in urea/SDS/Tris buffer, and then in the same buffer containing 2.5% (w/v) iodoacetamide. The run in the second dimension was performed on 9 to 16.5% polyacrylamide linear gradient gels with a constant current of 40 mA per gel at 10°C. The gels were stained with ammoniacal silver nitrate or colloidal Coomassie G-250 [15].

Evaluation and protein identification

The Versadoc Imaging System Model 3000 (Bio-Rad, Richmond, CA, USA) scanned the gels, which the PD QUEST 7.1 software (Bio-Rad) then analyzed. The total number of spots, the non-matched spots and the spot parameters were measured. To detect differentially expressed protein spots in SScFib+ compared with those in SScFib- patients, the software was instructed to create one reference map for each patient group. The software established these maps by taking into account only the spots that were constantly expressed in each patient of the same group. At least two gels from each patient were evaluated. Initially, we compared the two reference maps so as to assess differences in spot quantity between the two study groups. The PD QUEST 7.1 software determined the spot quantity by formula: Spot height × π × σx × σy (where the spot height represented the peak of the spot's Gaussian representation, and σx and σy were the SD of the spot's Gaussian distribution in the directions of the x and y axes, respectively) normalized the value for the total protein content of each gel. The differences between the two study groups were then confirmed by analysing the spot quantities observed in single patients. On the basis of the recent guidelines for proteomics research [16], non-matched spots and spots that differed significantly in quantity (p < 0.05) were regarded as differentially expressed in SScFib+ compared with SScFib- patients.

Proteins were identified by comparing the BALF maps obtained in this study with the SWISS-2D PAGE human plasma map [17] and published BALF maps [5,6], using immunoblotting, matrix-assisted laser desorption/ionization MS, and/or liquid chromatography MS/MS. For the MS analysis, the selected spots, excised from Coomassie-stained gels, were analyzed in a Voyager DE-PRO mass spectrometer (Applied Biosystems, Foster City, CA, USA), equipped with a reflectron analyzer and used in delayed extraction mode. Mass signals were used for database searching with the MASCOT peptide fingerprinting search program (Matrix Science, Boston, MA, USA). A quadrupole time-of-flight. Ultima hybrid mass spectrometer (Micromass, Toronto, Ontario, Canada) was used for the liquid chromatography–MS/MS analysis. The instrument was set up in a data-dependent MS/MS mode, and the raw MS and MS/MS spectra were elaborated with ProteinLynx software. The MASCOT MS/MS ion search software for protein identification was used. These evaluations were performed at CEINGE Biotecnologie Avanzate s.c. a r.l., University Federico II, Naples, Italy).

Statistical methods

Results are presented as mean ± SD or median and interquartile range. Normally distributed variables were analyzed by a two-tailed Student's t test. Proteomics expression data were compared by using the Mann–Whitney U test. For all tests p < 0.05 was regarded as significant. Analyses were performed with PRISM 3.0 (GraphPad Software, San Diego, CA, USA).

Results

BAL was performed in 15 SSc patients, including 9 patients with clinical, functional and HRCT signs of interstitial lung fibrosis (SScFib+ patients) and 6 patients who had no signs and symptoms of lung involvement (SScFib- patients). No clinical or microbiological evidence of bacterial or fungal infections was ever found in the included patients. Furthermore, the two patient groups revealed no significant difference in total BAL cells recovered, CD4+/CD8+ T-cell ratio, protein content, or differential BAL cell counts, although the SScFib+ patients displayed a trend toward higher neutrophil and eosinophil counts (Table 2). Neutrophil and eosinophil counts, as expected, were significantly higher in the SScFib+ patients than in data obtained in our laboratory from a group of healthy volunteers [12].

Table 2. Cytology, CD4+/CD8+ T-cell ratio and protein contents of bronchoalveolar lavage samples

BALF proteome in SScFib+ and SScFib- patients

Two-dimensional gel electrophoresis analyzed the whole protein profile of BALF from SScFib+ and SScFib- patients, to evaluate possible differences in protein expression between the two states of the disease. The mean number of spots, of which several were organized as spot-trains, in gels of BALF from SScFib+ and SScFib- patients was 365 ± 84 and 390 ± 75, respectively. However, only 332 and 348 of these spots were constantly expressed in BALF from all single SScFib+ and SScFib- patients, respectively. Figure 1 shows a representative Coomassie-stained gel map from an SScFib+ patient (Figure 1a) and an SScFib- patient (Figure 1b). By comparing the quantity of 59 individual spots and 12 spot-trains, we identified 35 spots and 12 spot-trains whose quantity did not vary significantly between SScFib+ and SScFib- patients (Mann–Whitney U test p > 0.05). By matching these gel maps with published two-dimensional BALF maps, we identified 30 proteins corresponding to the 47 spots and spot-trains that did not vary in quantity between the two patient groups (Table 3). Immunoblotting also validated the assignment of some of these proteins. Furthermore, we detected 24 individual spots that showed a reproducible, significant variation between the two study groups. The quantity in 21 of these spots was significantly increased, whereas the quantity in 3 spots was significantly decreased in SScFib+ patients compared with SScFib- patients.

thumbnailFigure 1. Representative Coomassie-stained gels of bronchoalveolar lavage fluid. Samples shown were taken from a systemic sclerosis patient with lung fibrosis (SScFib+) (a) and a systemic sclerosis patient without lung fibrosis (SScFib-) (b). Analyzed spots are marked with a number and the corresponding identified proteins are listed in Tables 3 and 4. Proteins whose expression was significantly different between SScFib+ patients and SScFib- patients are also indicated by name.

Table 3. Proteins whose quantity in BALF did not significantly vary between SScFib+ and SScFib- patients

Matrix-assisted laser desorption/ionization MS with or without liquid chromatography–MS/MS analysis identified the proteins corresponding to 21 spots that were constantly and significantly expressed in a different way between the two study groups. A comparison with published two-dimensional BALF maps followed by immunoblotting validation identified the proteins corresponding to the remaining three spots with the aforementioned criteria (Table 4). These 24 differently expressed spots corresponded to 11 proteins/protein fragments in total: 13 spots corresponded to serum albumin fragments, 7 of them corresponded to 5 previously recognized BALF proteins (α1-acid glycoprotein (2 spots), haptoglobin-α chain (2 spots), calgranulin (Cal) B, Cu–Zn superoxide dismutase (SOD) and glutathione S-transferase P (GSTP)), and 3 spots corresponded to 4 proteins that, to our knowledge, had not previously been described in published BALF two-dimensional maps (calumenin and cytohesin-2 (1 spot), cystatin SN and a fragment of mtDNA TOP1). One protein spot was marked as not determined because its identification gave a score that indicated uncertain identification. SScFib+ patients showed a significant upregulation of α1-acid glycoprotein, haptoglobin-α chain, Cal B, calumenin, and cytohesin-2 levels compared with SScFib- patients. Furthermore, the expression of a fragment of mtDNA TOP1 was exclusively detectable in SScFib+ patients, including two patients who were negative for anti-Scl70 serum antibodies. Finally, whereas Cu–Zn SOD was significantly downregulated, GSTP and cystatin SN were not detectable in SScFib+ patients in contrast with SScFib- patients.

Table 4. BALF proteins whose regulation in SScFib+ and SScFib- patients is different

Discussion

The pathogenesis of SSc is extremely complex, and no single unifying hypothesis or pathogenetic mechanism can explain all the aspects of this disease. It is therefore widely accepted that functional alterations of several cell effectors, including fibroblasts, endothelial cells, and T and B lymphocytes, are intimately involved in the development of the clinical and pathological manifestations of SSc [7,18,19]. Abnormalities in lung function occur in about 70% of SSc patients and currently represent the main cause of mortality in this population [7]. However, the factors that drive the severe and progressive visceral fibrosis remain mostly undetermined. Unlike the recent pathogenetic hypothesis for idiopathic interstitial lung fibrosis, which assigns only a marginal role to inflammation, fibrogenesis in SSc-related lung involvement is generally thought to be the result of a complex series of interstitial immunoinflammatory reactions [20]. The persistent and unregulated activation of genes that encode various collagen and other extracellular matrix proteins is regarded as a crucial pathogenetic event [21,22]. Furthermore, an alteration in the production of pro-inflammatory and/or pro-fibrotic cytokines and chemokines, growth factors (in particular transforming growth factor-β), and signaling molecules also seems to have a relevant role in fibrogenesis [23,24]. The identification of proteins that are differently expressed in the airways of SScFib+ patients compared with patients with no signs or symptoms of lung involvement may cast light on the pathogenetic mechanism of the disease and may thereby indicate protein biomarkers that are useful for the diagnosis of lung involvement, for the monitoring of SSc progression, and for the identification of possible new therapeutic targets. In this context, the use of 2-DE and the mapping of BALF seem highly interesting.

Our results demonstrated that quantitative and qualitative differences can be found between patients with SSc-associated lung fibrosis and patients with SSc with no signs or symptoms of lung involvement. At least 24 well-defined spots showed significant and reproducible variations in relative abundance between the two patient groups. Some of these spots corresponded to previously described BALF proteins and protein fragments, namely α1-acid glycoprotein, GSTP, Cu–Zn SOD, haptoglobin-α chain, and calgranulin B, whereas 4 of the proteins found had not previously been described in published two-dimensional BALF maps, namely cytohesin-2, calumenin, cystatin SN, and human mtDNA TOP1 fragment. In SScFib+ patients, GSTP and cystatin SN were below the detection limit, whereas Cu–Zn SOD was downregulated. In contrast, α1-acid glycoprotein, calumenin, cytohesin-2, haptoglobin-α chain, and calgranulin B were significantly upregulated, and the expression of mtDNA TOP1 was observed only in SScFib+ patients.

On the basis of these preliminary results, we can infer that 2-DE analysis of BALF can provide useful insight into the understanding of mechanisms involved in lung fibrogenesis through the identification of proteins that are deregulated in SSc-associated lung fibrosis. However, our results, as well as those of previous studies, clearly indicated that 2-DE analysis did not provide an exhaustive identification of all proteins that can be present in BALF, especially those of low molecular mass such as cytokines, chemokines, growth factors, and signaling molecules. Because these molecules are thought to be relevant to the pathogenesis of SSc-associated lung fibrosis, a combination of 2-DE analysis and proteomic approaches that specifically address the identification of these factors is necessary for the assessment of the whole protein pattern of BALF. Despite these considerations, most of the proteins we found differently regulated between SScFib+ patients and SScFib- patients could have a role in the development of lung fibrosis, whereby some of them are involved in the mechanisms that protect against lung injury or inflammation whereas others are involved in the mechanisms that drive fibroproliferation.

Oxidative stress is believed to be important in the pathogenesis of lung damage and in the development of lung fibrosis [25]. Among various enzymatic and non-enzymatic mechanisms that protect cells and tissues from oxidants [26,27], glutathione transferases [28] and SODs [29] are among such mechanisms that are thought to have a key protective role, especially in the lung. High levels of extracellular SODs are thought to have a protective role for lung matrix [29]. Recently, Tourkina and colleagues [30] demonstrated a deficiency in GSTP1 in scleroderma lung fibroblasts. The observation that GSTP and Cu–Zn SOD levels are severely downregulated in BALF from SScFib+ patients is in line with these findings, and confirms the relevance of these molecules as a defense tool for the lung against oxidant-induced damage and/or fibroproliferation.

Moreover, in BALF from SScFib+ patients, we did not detect levels of cystatin SN, which was, in contrast, well represented in SScFib- patients. Cystatin SN is a secreted protein, which belongs to SD-type or type-2 cystatins [31], which are potent inhibitors of CA clan mammalian cysteine peptidases. Intracellularly, these enzymes participate in normal protein turnover, in antigen and protein processing, and in apoptosis, whereas extracellularly they are involved in the inhibition of the proteolytic cascade [32]. The direct inhibition of endogenous and exogenous cysteine peptidases is the only function described so far for cystatin SN, suggesting that its function is to protect tissues against injury induced by these enzymes. However, recent results obtained with other type-2 cystatins seem to suggest a broader spectrum of activities, including the upregulation of IL-6 by human gingival fibroblasts, interferon-γ expression in CD4+ T cells [33,34], and the involvement in the differentiation and maturation of human dendritic cells [35].

Furthermore, we found an upregulation of at least six proteins in BALF from SScFib+ patients: haptoglobin-α chain, α1-acid glycoprotein, calumenin, cytohesin-2, Cal B, and mtDNA TOP1.

Haptoglobin and α1-acid glycoprotein are positive acute-phase proteins, whose plasma concentrations increase during inflammation [36]. The increased levels of both proteins in BALF from SScFib+ patients is likely to originate from the passive diffusion from plasma, as a result of the increased permeability of the air–blood barrier during the course of fibrosing alveolitis.

Calumenin is a member of the CREC family [37] that is secreted into the medium of cultured cells including fibroblasts [38] and early melanosomes [39]. Intracellularly, calumenin has a chaperone function in several Ca2+-regulated processes, but extracellularly its function is not yet fully understood. Vorum and colleagues found that calumenin binds to the serum amyloid P component, suggesting that it is involved in the formation of amyloid deposits in different tissues [40]. Coppinger and colleagues recently described the presence of calumenin in platelets and its release on platelet activation, as well as the protein's presence in human atherosclerotic lesions [41], therefore suggesting a possible role of this protein in leading to vascular injury through the promotion of platelet adhesion, fibrinogenesis, and intravascular thrombus deposition. Taking into account that a crucial pathogenetic step in SSc involves injury to microvasculature [19,20], it is possible to infer that calumenin could have a role in taking such an injury to lung level.

Cytohesin-2 is a member of a family of cytoplasmic signaling proteins [42], which may move from the cytosol to the plasma membrane after cell stimulation [43]. Although its biological function is mostly unknown, a recent study demonstrated that cytohesin-2 is an activator of the mitogen-activated protein (MAP) kinase signaling pathway [44]. Because MAP kinases are activator signals for lung fibroblasts [23], we suggest that cytohesin-2 might participate in the development and/or progression of lung fibrosis in SSc patients through the activation of the MAP kinase signaling pathways in lung fibroblasts. This hypothesis needs to be verified with further experimental observations.

Calgranulin B is an S100 protein that is unique together with Cal A in its myeloid-specific expression profile and in its abundance in neutrophils [45]. Increased levels of Cal B are present in the bronchial secretion of patients with chronic inflammatory disease, and these levels may induce the production of IL-8 by airway epithelial cells [46]. Furthermore, Viemann and colleagues demonstrated that the expression of Cal B and Cal A correlates with the inflammatory activity in systemic vasculitis, thereby confirming the role of these proteins in inflammatory reactions of endothelia [47]. Although the general consensus is that the Cal B function depends mainly on heterodimer formation (Cal B–Cal A), several studies have demonstrated that the monomer is also a potent stimulator of neutrophils and is involved in the recruitment of leukocytes to the site of inflammation through the regulation of adhesion and the extravasion of neutrophils [45,48]. Furthermore, recombinant Cal B and its homodimer stimulate the proliferation of rat fibroblasts, suggesting that this protein might also function as a mitogen for fibroblasts in chronic inflammation [49]. On the basis of these observations, Cal B could have a role in SSc-associated lung fibrosis through several pathways, including amplifying the inflammatory process by inducing the extravasion of neutrophils and the production of IL-8, inducing an inflammatory reaction in the endothelia, and/or stimulating lung fibroblast proliferation.

Finally, we found that a fragment of mtDNA TOP1 was detectable only in BALF from patients with interstitial lung fibrosis, including in two SScFib+ patients who were negative for serum anti-Scl70 antibodies. This protein fragment was never observed in BALF from SScFib- patients, including in two patients with positive anti-Scl70 antibodies. A common 13-exon motif and a similar amino-acid sequence characterize genes for mitochondrial and nuclear DNA TOP1, except for the N-terminal domain, which in mtDNA TOP1 contains a mitochondrial localization sequence instead of the nuclear localization signal [50]. Although we demonstrated that the presence of detectable levels of mtDNA TOP1 was a constant and particular feature of SScFib+ patients, we did not fully ascertain the antigenic role of this protein fragment and its relation with the development of lung fibrosis. Because autoantibodies against DNA TOP1 are strongly correlated with interstitial pulmonary involvement in SSc [51], further studies are warranted to assess the role and the frequency of this antigenic target in BALF.

Conclusion

On the basis of these preliminary results we believe that the comparative analysis of BALF proteome from SScFib+ and SScFib- patients by 2-DE might provide a useful insight into some relevant steps of lung fibrogenesis. SSc-associated lung fibrosis is a multifaceted process involving the activation of T cells and epithelial cells, the secretion of pro-inflammatory cytokines and growth factors, and fibroproliferation (Figure 2). In addition, several factors, including activation of the coagulation cascade and oxidative stress, are thought to influence the development of lung fibrosis. At least six proteins that were differently regulated in BALF from SScFib+ patients and in BALF from SScFib- patients might have a role in the pathogenesis of SSc-associated interstitial lung disease. As shown in Figure 2, the upregulation of Cal B, cytohesin-2, and calumenin in BALF from SScFib+ patients could further promote the synthesis of pro-inflammatory cytokines, the influx of inflammatory cells, and fibrinogenesis, whereas the downregulation of GSTP, Cu–Zn SOD and cystatin SN could favor vascular and lung tissue injury through the impairment of mechanisms that protect against oxidants and cysteine peptidases. However, further animal and human studies will be necessary both to assess the actual role of each of these factors in the development of SSc-associated lung fibrosis and to determine whether these factors are relevant as disease biomarkers, and if so which ones. Conclusions from these studies could enable us to predict which patients will develop progressive pulmonary fibrosis.

thumbnailFigure 2. Hypothetical role of some disregulated BALf proteins in mechanisms driving SSc-related lung fibrosis. Inflammation is thought to be the main mechanism driving lung fibrosis in scleroderma patients. In this complex inflammatory process several pathways are involved, including the activation of T cells and epithelial cells, the secretion of pro-inflammatory cytokines and growth factors, and fibroblast proliferation. Furthermore, products from the coagulation cascade and oxidative stress may contribute to fibrogenesis. The upregulation of calgranulin B (Cal B), cytohesin-2 and calumenin might favor inflammation and fibrogenesis, whereas the downmodulation of the protective factors glutathione S-transferase P (GSTP), Cu–Zn superoxide dismutase (SOD) and cystatin SN may amplify tissue injury and inflammation. MMP, matrix metalloproteinases; TIMP, tissue inhibitor of matrix metalloproteinases; ROS, reactive oxygen species; RNS, reactive nitrogen species; O2-, superoxide; H2O2, hydrogen peroxide; NO, nitric oxide; SScFib+, systemic sclerosis patients with lung fibrosis; SScFib-, systemic sclerosis patients without lung fibrosis.

Abbreviations

Anti-Scl70 = anti-topoisomerase I antibodies; BAL = bronchoalveolar lavage; BALF = bronchoalveolar lavage fluid; Cal = calgranulin; 2-DE = two-dimensional gel electrophoresis; GSTP = glutathione S-transferase P; HRCT = high-resolution computed tomography; IL = interleukin; IPG = immobilized pH gradient; MAP = mitogen-activated protein; MS, mass spectrometry; mtDNA TOP1 = mitochondrial DNA topoisomerase 1; SOD = superoxide dismutase; SSc = systemic sclerosis; SScFib- = systemic sclerosis patients without lung fibrosis; SScFib+ = systemic sclerosis patients with lung fibrosis; TLCO = carbon monoxide transfer.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

FAM generated and planned the project, supervised the work and wrote the manuscript. BAM and SR contributed equally to perform the research, analyzed critically data and participated in the preparation of the manuscript. PI assisted in designing the experiments and conducted 2-DE and immunoblotting. MM was involved in data analysis and performed statistical analysis. CL and CV selected patients and revised all clinical charts. PE was involved in the coordination of the study and in the discussion and revision of the manuscript. MF participated in the study design, supervised the work, read the bronchoalveolar lavage and helped to draft the manuscript. MC participated in the study design and its coordination and participated in preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Dr Angela Flagiello for help with mass analysis, and Professor Piero Pucci for insightful comments on the manuscript. This work was supported by Fondazione Cariplo, Italy (Grant Rif.2003.1644/10.8485).

References

  1. Wattiez R, Hermans C, Bernard A, Lesur O, Falmagne P: Human bronchoalveolar lavage fluid: two-dimensional gel electrophoresis, amino acid microsequencing and identification of major proteins.

    Electrophoresis 1999, 20:1634-1645. PubMed Abstract | Publisher Full Text OpenURL

  2. Wattiez R, Hermans C, Cruyt C, Bernard A, Falmagne P: Human bronchoalveolar lavage fluid protein two-dimensional database: study of interstitial lung diseases.

    Electrophoresis 2000, 21:2703-2712. PubMed Abstract | Publisher Full Text OpenURL

  3. Magi B, Bini L, Perari MG, Fossi A, Sanchez JC, Hochstrasser D, Paesano S, Raggiaschi R, Santucci A, Pallini V, et al.: Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study.

    Electrophoresis 2002, 23:3434-3444. PubMed Abstract | Publisher Full Text OpenURL

  4. Sabounchi-Schutt F, Astrom J, Hellman U, Eklund A, Grunewald J: Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach.

    Eur Respir J 2003, 21:414-420. PubMed Abstract | Publisher Full Text OpenURL

  5. Wattiez R, Falmagne P: Proteomics of bronchoalveolar lavage fluid.

    J Chromatogr B Analyt Technol Biomed Life Sci 2005, 815:169-178. PubMed Abstract | Publisher Full Text OpenURL

  6. Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E, Cianti R, Bini L, Pallini V: Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis.

    Proteomics 2005, 5:1423-1430. PubMed Abstract | Publisher Full Text OpenURL

  7. Jimenez SA, Derk CT: Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis.

    Ann Intern Med 2004, 140:37-50. PubMed Abstract | Publisher Full Text OpenURL

  8. Basu D, Reveille JD: Anti-scl-70.

    Autoimmunity 2005, 38:65-72. PubMed Abstract | Publisher Full Text OpenURL

  9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostics and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma).

    Arthritis Rheum 1980, 21:581-590. OpenURL

  10. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, et al.: A disease severity scale for systemic sclerosis: development and testing.

    J Rheumatol 1999, 26:2159-2167. PubMed Abstract OpenURL

  11. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP 3rd, Toews G: Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring.

    AJR Am J Roentgenol 1997, 169:977-983. PubMed Abstract OpenURL

  12. Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM, Patrizio V, Bobbio-Pallavicini F, Pozzi E, Montecucco C: BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis.

    Sarcoidosis Vasc Diffuse Lung Dis 2004, 21:111-118. PubMed Abstract OpenURL

  13. Report of the European Society of Pneumology Task Group: Technical recommendations and guidelines for bronchoalveolar lavage (BAL).

    Eur Respir J 1989, 2:561-585. PubMed Abstract OpenURL

  14. Görg A, Postel W, Günther S: The current state of two-dimensional electrophoresis with immobilized pH gradients.

    Electrophoresis 1988, 9:531-546. PubMed Abstract | Publisher Full Text OpenURL

  15. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, Orecchia P, Zardi L, Righetti PG: Blue Silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis.

    Electrophoresis 2004, 25:1327-1333. PubMed Abstract | Publisher Full Text OpenURL

  16. Wilkins MR, Appel RD, Van Eyk JE, Chung MCM, Gorg A, Hecker M, Huber LA, Langen H, Link AJ, Paik Y, et al.: Guidelines for the next 10 years of proteomics.

    Proteomics 2006, 6:4-8. PubMed Abstract | Publisher Full Text OpenURL

  17. ExPASY Proteomics Server [http://www.expasy.ch/] webcite

  18. Ludwicka-Bradley A, Bogatkevich G, Silver RM: Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma).

    Clin Exp Rheumatol 2004, 2(3 Suppl 33):S38-S46. OpenURL

  19. Kahaleh MB: Vascular involvement in systemic sclerosis (SSc).

    Clin Exp Rheumatol 2004, 2(3 Suppl 33):S19-S23. OpenURL

  20. Steen VD: The lung in systemic sclerosis.

    J Clin Rheumatol 2005, 11:40-46. PubMed Abstract | Publisher Full Text OpenURL

  21. Pannu J, Trojanowska M: Recent advances in fibroblast signaling and biology in scleroderma.

    Curr Opin Rheumatol 2004, 16:739-745. PubMed Abstract | Publisher Full Text OpenURL

  22. Postlethwaite AE, Shigemitsu H, Kanangat S: Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis.

    Curr Opin Rheumatol 2004, 16:733-738. PubMed Abstract | Publisher Full Text OpenURL

  23. Christner PJ, Jimenez SA: Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches.

    Curr Opin Rheumatol 2004, 16:746-752. PubMed Abstract | Publisher Full Text OpenURL

  24. Atamas SP, White B: The role of chemokines in the pathogenesis of scleroderma.

    Curr Opin Rheumatol 2003, 15:772-777. PubMed Abstract | Publisher Full Text OpenURL

  25. Kinnula VL, Fattman CL, Tan RJ, Oury TD: Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy.

    Am J Respir Crit Care Med 2005, 172:417-422. PubMed Abstract | Publisher Full Text OpenURL

  26. Kinnula VL: Focus on antioxidant enzymes and antioxidant strategies smoking in related airway diseases.

    Thorax 2005, 60:693-700. PubMed Abstract | Publisher Full Text OpenURL

  27. Comhair SA, Erzurum SC: Antioxidant responses to oxidant-mediated lung diseases.

    Am J Physiol Lung Cell Mol Physiol 2002, 283:L246-L255. PubMed Abstract | Publisher Full Text OpenURL

  28. Hayes JD, Flanagan JU, Jowsey IR: Glutathione transferases.

    Annu Rev Pharmacol Toxicol 2005, 45:51-88. PubMed Abstract | Publisher Full Text OpenURL

  29. Kinnula VL, Crapo JD: Superoxide dismutases in the lung and human lung diseases.

    Am J Respir Crit Care Med 2003, 167:1600-1619. PubMed Abstract | Publisher Full Text OpenURL

  30. Tourkina E, Gooz P, Oates JC, Ludwicka-Bradley A, Silver RM, Hoffman S: Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon.

    Am J Respir Cell Mol Biol 2004, 31:28-35. PubMed Abstract | Publisher Full Text OpenURL

  31. Abrahamson M, Alvarez-Fernandez M, Nathanson CM: Cystatins.

    Biochem Soc Symp 2003, 70:179-199. PubMed Abstract OpenURL

  32. Dickinson DP: Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease.

    Crit Rev Oral Biol Med 2002, 13:238-275. PubMed Abstract | Publisher Full Text OpenURL

  33. Kato T, Imatani T, Miura T, Minaguchi K, Saitoh E, Okuda K: Cytokine-inducing activity of family 2 cystatins.

    Biol Chem 2000, 381:1143-1147. PubMed Abstract | Publisher Full Text OpenURL

  34. Kato T, Ito T, Imatani T, Minaguchi K, Saitoh E, Okuda K: Cystatin SA, a cysteine proteinase inhibitor, induces interferon-γ expression in CD4-positive T cells.

    Biol Chem 2004, 385:419-422. PubMed Abstract | Publisher Full Text OpenURL

  35. Zavasnik-Bergant T, Repnik U, Schweiger A, Romih R, Jeras M, Turk V, Kos J: Differentiation- and maturation-dependent content, localization, and secretion of cystatin C in human dendritic cells.

    J Leukoc Biol 2005, 78:122-134. PubMed Abstract | Publisher Full Text OpenURL

  36. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation.

    N Engl J Med 1999, 340:448-454. PubMed Abstract | Publisher Full Text OpenURL

  37. Honore B, Vorum H: The CREC family, a novel family of multiple EF-hand, low-affinity Ca2+-binding proteins localised to the secretory pathway of mammalian cells.

    FEBS Lett 2000, 466:11-18. PubMed Abstract | Publisher Full Text OpenURL

  38. Vorum H, Hager H, Christensen BM, Nielsen S, Honore B: Human calumenin localizes to the secretory pathway and is secreted to the medium.

    Exp Cell Res 1999, 248:473-481. PubMed Abstract | Publisher Full Text OpenURL

  39. Basrur V, Yang F, Kushimoto T, Higashimoto Y, Yasumoto K, Valencia J, Muller J, Vieira WD, Watabe H, Shabanowitz J, et al.: Proteomic analysis of early melanosomes: identification of novel melanosomal proteins.

    J Proteome Res 2003, 2:69-79. PubMed Abstract | Publisher Full Text OpenURL

  40. Vorum H, Jacobsen C, Honore B: Calumenin interacts with serum amyloid P component.

    FEBS Lett 2000, 465:129-134. PubMed Abstract | Publisher Full Text OpenURL

  41. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB: Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.

    Blood 2004, 103:2096-2104. PubMed Abstract | Publisher Full Text OpenURL

  42. Chardin P, Paris S, Antonny B, Robineau S, Beraud-Dufour S, Jackson CL, Chabre M: A human exchange factor for ARF contains Sec7- and pleckstrin-homology domains.

    Nature 1996, 384:481-484. PubMed Abstract | Publisher Full Text OpenURL

  43. Venkateswarlu K: Interaction protein for cytohesin exchange factors 1 (IPCEF1) binds cytohesin 2 and modifies its activity.

    J Biol Chem 2003, 278:43460-43469. PubMed Abstract | Publisher Full Text OpenURL

  44. Theis MG, Knorre A, Kellersch B, Moelleken J, Wieland F, Kolanus W, Famulok M: Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2.

    Proc Natl Acad Sci USA 2004, 101:11221-11226. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  45. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA: Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion.

    J Immunol 2003, 170:3233-3242. PubMed Abstract | Publisher Full Text OpenURL

  46. Ahmad A, Bayley DL, He S, Stockley RA: Myeloid related protein-8/14 stimulates interleukin-8 production in airway epithelial cells.

    Am J Respir Cell Mol Biol 2003, 29:523-530. PubMed Abstract | Publisher Full Text OpenURL

  47. Viemann D, Strey A, Janning A, Jurk K, Klimmek K, Vogl T, Hirono K, Ichida F, Foell D, Kehrel B, et al.: Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells.

    Blood 2005, 105:2955-2962. PubMed Abstract | Publisher Full Text OpenURL

  48. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, Foell D, Gerke V, Manitz MP, Nacken W, et al.: MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes.

    Blood 2004, 104:4260-4268. PubMed Abstract | Publisher Full Text OpenURL

  49. Shibata F, Miyama K, Shinoda F, Mizumoto J, Takano K, Nakagawa H: Fibroblast growth-stimulating activity of S100A9 (MRP-14).

    Eur J Biochem 2004, 271:2137-2143. PubMed Abstract | Publisher Full Text OpenURL

  50. Zhang H, Meng LH, Zimonjic DB, Popescu NC, Pommier Y: Thirteen-exon-motif segnature for vertebrate nuclear and mitochondrial type IB topoisomerases.

    Nucleic Acids Res 2004, 32:2087-2092. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  51. Steen VD, Powell DL, Medsger TA Jr: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

    Arthritis Rheum 1988, 31:196-203. PubMed Abstract OpenURL